{"news_desk": "Business", "print_page": "1", "section_name": "Business Day", "subsection_name": "DealBook", "byline": {"contributor": "Andrew Pollack contributed reporting.", "original": "By MATTHEW GOLDSTEIN, ALEXANDRA STEVENSON and PETER EAVIS", "person": [{"rank": 1, "role": "reported", "firstname": "Matthew", "organization": "", "lastname": "GOLDSTEIN"}, {"rank": 2, "role": "reported", "firstname": "Alexandra", "organization": "", "lastname": "STEVENSON"}, {"rank": 3, "role": "reported", "firstname": "Peter", "organization": "", "lastname": "EAVIS"}]}, "abstract": "Shares of Valeant Pharmaceutical fall after report by Citron Research accuses it of accounting fraud; report contends Valeant dealt in 'phantom sales;' Pershing Square Capital head William A Ackman increases share in company.", "type_of_material": "News", "word_count": "1305", "lead_paragraph": "A research firm\u2019s report that all but called Valeant the pharmaceutical equivalent of Enron hit the stock market like a bomb Wednesday morning.", "pub_date": "2015-10-22T00:00:00Z", "document_type": "article", "slideshow_credits": null, "headline": {"main": "Valeant\u2019s Shares Fall on Report\u2019s Fraud Claim", "print_headline": "Valeant\u2019s Shares Fall on Report\u2019s Fraud Claim"}, "snippet": "A research firm\u2019s report that all but called Valeant the pharmaceutical equivalent of Enron hit the stock market like a bomb Wednesday morning.", "multimedia": [{"height": 126, "url": "images/2015/10/22/business/22Valeant/22Valeant-thumbWide-v2.jpg", "legacy": {"widewidth": "190", "wideheight": "126", "wide": "images/2015/10/22/business/22Valeant/22Valeant-thumbWide-v2.jpg"}, "type": "image", "width": 190, "subtype": "wide"}, {"height": 399, "url": "images/2015/10/22/business/22Valeant/22Valeant-articleLarge.jpg", "legacy": {"xlargewidth": "600", "xlargeheight": "399", "xlarge": "images/2015/10/22/business/22Valeant/22Valeant-articleLarge.jpg"}, "type": "image", "width": 600, "subtype": "xlarge"}, {"height": 75, "url": "images/2015/10/22/business/22Valeant/22Valeant-thumbStandard-v2.jpg", "legacy": {"thumbnailwidth": "75", "thumbnail": "images/2015/10/22/business/22Valeant/22Valeant-thumbStandard-v2.jpg", "thumbnailheight": "75"}, "type": "image", "width": 75, "subtype": "thumbnail"}], "web_url": "http://www.nytimes.com/2015/10/22/business/dealbook/valeants-shares-fall-on-reports-fraud-claim.html", "keywords": [{"rank": "1", "is_major": "Y", "value": "Valeant Pharmaceuticals International Inc", "name": "organizations"}, {"rank": "2", "is_major": "Y", "value": "Pershing Square Capital Management", "name": "organizations"}, {"rank": "3", "is_major": "Y", "value": "Ackman, William A", "name": "persons"}, {"rank": "4", "is_major": "N", "value": "Drugs (Pharmaceuticals)", "name": "subject"}, {"rank": "5", "is_major": "N", "value": "Paulson & Co", "name": "organizations"}, {"rank": "6", "is_major": "N", "value": "Suits and Litigation (Civil)", "name": "subject"}, {"rank": "7", "is_major": "N", "value": "Pearson, John Michael (1959- )", "name": "persons"}, {"rank": "8", "is_major": "N", "value": "Hedge Funds", "name": "subject"}, {"rank": "9", "is_major": "N", "value": "Citron Research", "name": "organizations"}], "blog": [], "_id": "562840d138f0d80f1ae08bf1", "source": "The New York Times"}